Expert Insight Into:
The Relation Between Inflammation and Neurodegeneration in Multiple Sclerosis Brains
Medical Writer: Shawn Kuhmann, PhD
Expert Faculty: Suhayl Dhib-Jalbut, MD
Medical Writer: Shawn Kuhmann, PhD
Expert Faculty: Suhayl Dhib-Jalbut, MD
Click here to view our current activities in Neurology.
Dr. Suhayl Dhib-Jalbut reviews a study that analyzed the interdependence of inflammation, neurodegeneration, and disease progression in various multiple sclerosis stages in relation to lesional activity and clinical course, with a particular focus on progressive multiple sclerosis.
Suhayl Dhib-Jalbut, MD
- Professor and Chairman
- Department of Neurology
- UMDNJ-Robert Wood Johnson Medical School
- New Brunswick, NJ
Tracy M. DeAngelis, MD, is a consultant for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD, has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP, has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD, has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Aaron E. Miller, MD, has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience; and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Available for CME/CE:
Physicians
Publish Date: Jun 15, 2010 Termination Date: Jun 15, 2011Nurses
Publish Date: Jun 15, 2010 Termination Date: Jun 15, 2011Pharmacists
Publish Date: Jun 15, 2010 Termination Date: Jun 15, 2011Estimated time for completion of this activity:
CNE: 33.00 minutes
CPE: 45.00 minutes
Target Audience
This activity is designed for neurologists and other clinicians who specialize in and care for patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with multiple sclerosis.
Learning Objective (s)
- Evaluate the role that inflammation plays in neurodegeneration in patients with progressive MS so that future MS therapies targeting inflammation may be appraised.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.55 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-10-1103-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Suhayl Dhib-Jalbut, MD has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Shawn E. Kuhmann, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Anne H. Cross, MD has received grant/research support from Acorda Therapeutics, Genentech, Inc and Sanofi-Aventis; is on the speakers bureau for Bayer Healthcare and Teva Neuroscience; and is on the advisory boards of Bayer Healthcare, Biogen Idec, BioMS Medical, and Eli Lilly and Company.
Tracy M. DeAngelis, MD is a consultant for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Aaron E. Miller, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience; and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Biogen Idec
Genentech, Inc.
Teva Neuroscience.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Jun 15, 2010 Termination Date: Jun 15, 2011Nurses
Publish Date: Jun 15, 2010 Termination Date: Jun 15, 2011Pharmacists
Publish Date: Jun 15, 2010 Termination Date: Jun 15, 2011Estimated time for completion of this activity:
CNE: 33.00 minutes
CPE: 45.00 minutes
Target Audience
This activity is designed for neurologists and other clinicians who specialize in and care for patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with multiple sclerosis.
Learning Objective (s)
- Evaluate the role that inflammation plays in neurodegeneration in patients with progressive MS so that future MS therapies targeting inflammation may be appraised.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.55 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-10-1103-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Suhayl Dhib-Jalbut, MD has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Shawn E. Kuhmann, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Anne H. Cross, MD has received grant/research support from Acorda Therapeutics, Genentech, Inc and Sanofi-Aventis; is on the speakers bureau for Bayer Healthcare and Teva Neuroscience; and is on the advisory boards of Bayer Healthcare, Biogen Idec, BioMS Medical, and Eli Lilly and Company.
Tracy M. DeAngelis, MD is a consultant for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD has received grant/research support from Bayer, Serono and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience; and is on the speakers bureau for Bayer and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Aaron E. Miller, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience; and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Biogen Idec
Genentech, Inc.
Teva Neuroscience.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
||||||||||||||||||||||||||||||||||||||



